

Eamonn M M Quigley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9169088/publications.pdf>

Version: 2024-02-01

207
papers

17,343
citations

26630
56
h-index

14208
128
g-index

233
all docs

233
docs citations

233
times ranked

12226
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Trials of Probiotics in Patients With Irritable Bowel Syndrome: Some Points to Consider. <i>Journal of Neurogastroenterology and Motility</i> , 2022, 28, 204-211.	2.4	11
2	Small Intestinal Bacterial Overgrowthâ€™ Pathophysiology and Its Implications for Definition and Management. <i>Gastroenterology</i> , 2022, 163, 593-607.	1.3	33
3	Editorial: risky business. What do sufferers' perceptions of risk from interventions for irritable bowel syndrome really mean?. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1218-1219.	3.7	1
4	Lost microbes of COVID-19: <i>Bifidobacterium</i> , <i>Faecalibacterium</i> depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000871.	2.7	39
5	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	1.3	913
6	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14070.	3.0	17
7	Low FODMAP (fermentable oligo-, di-, monosaccharides, and polyol) diet goes global. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1394-1395.	4.7	0
8	The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 649-667.	17.8	701
9	Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100171.	3.0	8
10	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8047-8061.	3.6	5
11	The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 689-711.	2.2	1
12	Reply to: Postbiotics â€™ when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 827-828.	17.8	24
13	Esophageal stricture: Not your usual culprit?. <i>Gastroenterology</i> , 2021, , .	1.3	1
14	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	12.1	122
15	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. <i>Frontline Gastroenterology</i> , 2020, 11, 62-69.	1.8	26
16	Nutraceuticals as modulators of gut microbiota: Role in therapy. <i>British Journal of Pharmacology</i> , 2020, 177, 1351-1362.	5.4	28
17	Efficacy of soluble fibre, antispasmodic drugs, and gutâ€™brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	8.1	108
18	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020, 159, 1526-1532.	1.3	84

#	ARTICLE	IF	CITATIONS
19	The probiotic <i>Bifidobacterium</i> in the management of Coronavirus: A theoretical basis. International Journal of Immunopathology and Pharmacology, 2020, 34, 205873842096130.	2.1	36
20	Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation. Neurogastroenterology and Motility, 2020, 32, e13890.	3.0	19
21	Commentary: faecal microbiota transplantation “from home brew to holy grail. Alimentary Pharmacology and Therapeutics, 2020, 51, 208-209.	3.7	0
22	Peppermint Oil in Irritable Bowel Syndrome. Gastroenterology, 2020, 159, 395-396.	1.3	7
23	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut, 2020, 69, 1441-1451.	12.1	137
24	Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. Indian Journal of Gastroenterology, 2020, 39, 9-21.	1.4	29
25	Editorial: the microbiome, aspirin and colorectal cancer. Alimentary Pharmacology and Therapeutics, 2020, 52, 1740-1741.	3.7	1
26	Recent advances in modulating the microbiome. F1000Research, 2020, 9, 46.	1.6	36
27	Irritable bowel syndrome in celiac disease - relationships to celiac disease antibodies and levels of pro-inflammatory cytokines. Revista De Gastroenterologia Del Peru: Organo Oficial De La Sociedad De Gastroenterologia Del Peru, 2020, 40, 127-135.	0.2	0
28	Systematic review with meta-analysis: cholecystectomy for biliary dyskinesia “what can the gallbladder ejection fraction tell us?. Alimentary Pharmacology and Therapeutics, 2019, 49, 654-663.	3.7	18
29	Symptoms and the small intestinal microbiome “the unknown explored. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 457-458.	17.8	7
30	Editorial: Lactobacillus GG for diarrhoea in children “reports of its demise have been premature!. Alimentary Pharmacology and Therapeutics, 2019, 49, 1533-1534.	3.7	1
31	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors’ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1254-1255.	3.7	1
32	Microbiome Modulation in Liver Disease. Clinical Liver Disease, 2019, 14, 149-151.	2.1	0
33	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2019, 114, 21-39.	0.4	303
34	Prebiotics and Probiotics in Digestive Health. Clinical Gastroenterology and Hepatology, 2019, 17, 333-344.	4.4	215
35	The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). Current Gastroenterology Reports, 2019, 21, 3.	2.5	79
36	Therapeutic implications of the gastrointestinal microbiome. Current Opinion in Pharmacology, 2018, 38, 90-96.	3.5	13

#	ARTICLE	IF	CITATIONS
37	The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region –background and recommendations of a regional consensus meeting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 57-69.	2.8	24
38	Definition, Pathogenesis, and Management of That“Cursed”Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 467-479.	4.4	35
39	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018, 67, 1425-1433.	12.1	27
40	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1044-1060.	3.7	423
41	“Brain Foggiess”™ and D-Lactic Acidosis: Probiotics Are Not the Cause. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e187.	2.5	12
42	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	1.3	119
43	The diagnosis of small intestinal bacterial overgrowth: Two steps forward, one step backwards?. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13494.	3.0	16
44	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1-18.	0.4	262
45	Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , 2018, 35, 967-980.	2.9	24
46	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1290-1300.	0.4	269
47	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 355-366.	2.4	13
48	The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). <i>Journal of Clinical Medicine</i> , 2018, 7, 6.	2.4	73
49	Autoimmune liver disease and the enteric microbiome. <i>AIMS Microbiology</i> , 2018, 4, 334-346.	2.2	3
50	A Critical Review of the Current Clinical Landscape of Gastroparesis. <i>Gastroenterology and Hepatology</i> , 2018, 14, 140-145.	0.1	6
51	Highlights of the Updated Evidence-Based IBS Treatment Monograph. <i>Gastroenterology and Hepatology</i> , 2018, 14, 665-667.	0.1	0
52	Basic Definitions and Concepts: Organization of the Gut Microbiome. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 1-8.	2.2	15
53	What can we learn from other clinical settings on the influence of the gut microbiome on the brain?. <i>Clinical Liver Disease</i> , 2017, 9, 52-54.	2.1	2
54	Editorial: food for thought—the low FODMAP diet and IBS in perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 206-207.	3.7	3

#	ARTICLE	IF	CITATIONS
55	Editorial: diet, inflammation and irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1278-1279.	3.7	1
56	Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 315-320.	17.8	96
57	Probiotics in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 769-782.	2.2	131
58	The <scp>PAC</scp>â€<scp>SYM</scp> questionnaire for chronic constipation: defining the minimal important difference. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1103-1111.	3.7	54
59	Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 94.	4.2	513
60	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Current Gastroenterology Reports</i> , 2017, 19, 53.	2.5	33
61	The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , 2017, 34, 2661-2673.	2.9	45
62	The Microbiome and the Liver: The Basics. <i>Seminars in Liver Disease</i> , 2016, 36, 299-305.	3.6	13
63	The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome. <i>Seminars in Liver Disease</i> , 2016, 36, 312-316.	3.6	21
64	Primary Biliary Cirrhosis and the Microbiome. <i>Seminars in Liver Disease</i> , 2016, 36, 349-353.	3.6	13
65	The Microbiome: What Will the Future Hold?. <i>Seminars in Liver Disease</i> , 2016, 36, 354-359.	3.6	4
66	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2357-2372.	2.3	68
67	Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators. <i>Journal of Digestive Diseases</i> , 2016, 17, 572-581.	1.5	41
68	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16014.	30.5	674
69	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 199-212.	3.2	63
70	Advancing treatment options for chronic idiopathic constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 501-511.	1.8	13
71	Editorial: allergy and recurrent abdominal pain of childhood/irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 229-229.	3.7	1
72	Probiotics in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, S60-S64.	2.2	26

#	ARTICLE	IF	CITATIONS
73	THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. Arquivos De Gastroenterologia, 2015, 52, 331-338.	0.8	18
74	Prokinetics in the Management of Functional Gastrointestinal Disorders. Journal of Neurogastroenterology and Motility, 2015, 21, 330-336.	2.4	41
75	Pharmacoeconomic study of chronic constipation in a secondary care centre. Irish Journal of Medical Science, 2015, 184, 863-870.	1.5	5
76	Diet and irritable bowel syndrome. Current Opinion in Gastroenterology, 2015, 31, 166-171.	2.3	19
77	Editorial: differentiating chronic idiopathic constipation from constipationâ€predominant irritable bowel syndrome â€ possible and important?. Alimentary Pharmacology and Therapeutics, 2015, 41, 1299-1299.	3.7	7
78	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. Clinical and Translational Gastroenterology, 2015, 6, e107.	2.5	48
79	Leadership in Medicine: Do We Need a New Approach?. American Journal of Gastroenterology, 2014, 109, 786-788.	0.4	0
80	Commentary: probing probiotics in cirrhosis â€ a template for future studies?. Alimentary Pharmacology and Therapeutics, 2014, 39, 1334-1335.	3.7	2
81	Small intestinal bacterial overgrowth. Current Opinion in Gastroenterology, 2014, 30, 141-146.	2.3	77
82	Manipulation of the Microbiota for Treatment of IBS and IBDâ€Challenges and Controversies. Gastroenterology, 2014, 146, 1554-1563.	1.3	149
83	The Future of Probiotics for Disorders of the Brain-Gut Axis. Advances in Experimental Medicine and Biology, 2014, 817, 417-432.	1.6	14
84	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2014, 109, 1547-1561.	0.4	595
85	The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2014, 109, 1367-1374.	0.4	258
86	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. American Journal of Gastroenterology, 2014, 109, S2-S26.	0.4	503
87	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2014, 109, 1350-1365.	0.4	335
88	The past 10 years of gastroenterology and hepatologyâ€reflections and predictions. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 692-700.	17.8	2
89	Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon!. Indian Journal of Medical Research, 2014, 140, 582-4.	1.0	7
90	Editorial: PARs for the Course: Roles of Proteases and PAR Receptors in Subtly Inflamed Irritable Bowel Syndrome. American Journal of Gastroenterology, 2013, 108, 1644-1646.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Bugs on the brain; brain in the gut“seeking explanations for common gastrointestinal symptoms. Irish Journal of Medical Science, 2013, 182, 1-6.	1.5	23
92	Emerging treatments for chronic constipation. Expert Opinion on Emerging Drugs, 2013, 18, 365-373.	2.4	8
93	Commentary: synbiotics and gut microbiota in older people - a microbial guide to healthy ageing. Alimentary Pharmacology and Therapeutics, 2013, 38, 1141-1142.	3.7	10
94	A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Current Medical Research and Opinion, 2013, 29, 149-160.	1.9	19
95	Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes, 2013, 4, 201-211.	9.8	99
96	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013, 4, 325-339.	9.8	342
97	Prucalopride: safety, efficacy and potential applications. Therapeutic Advances in Gastroenterology, 2012, 5, 23-30.	3.2	57
98	Portrait of an immunoregulatory bifidobacterium. Gut Microbes, 2012, 3, 261-266.	9.8	104
99	<i>Bifidobacterium infantis</i> 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut, 2012, 61, 354-366.	12.1	242
100	Carriage of Clostridium difficile in outpatients with irritable bowel syndrome. Journal of Medical Microbiology, 2012, 61, 1290-1294.	1.8	15
101	A Global Perspective on Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2012, 46, 356-366.	2.2	124
102	Epigenetics: filling in the 'heritability gap' and identifying gene-environment interactions in ulcerative colitis. Genome Medicine, 2012, 4, 72.	8.2	12
103	An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut, 2012, 61, 997-1006.	12.1	742
104	Commentary: long-term lubiprostone for constipation predominant IBS. Alimentary Pharmacology and Therapeutics, 2012, 35, 962-963.	3.7	1
105	Prebiotics and Probiotics. Nutrition in Clinical Practice, 2012, 27, 195-200.	2.4	74
106	Systematic review: cardiovascular safety profile of 5-HT ₄ agonists developed for gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 2012, 35, 745-767.	3.7	236
107	CT-based estimation of intracavitary gas volumes using threshold-based segmentation: In vitro study to determine the optimal threshold range. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 289-294.	1.8	8
108	Barrett's esophagus: clinical features, obesity, and imaging. Annals of the New York Academy of Sciences, 2011, 1232, 36-52.	3.8	4

#	ARTICLE	IF	CITATIONS
109	Cisapride: What can we learn from the rise and fall of a prokinetic?. Journal of Digestive Diseases, 2011, 12, 147-156.	1.5	87
110	The enteric microbiota in the pathogenesis and management of constipation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 119-126.	2.4	81
111	Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride?. Clinical Medicine Gastroenterology, 2010, 3, CGast.S4136.	0.2	8
112	Bacteria, genetics and irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2010, 4, 271-276.	3.0	8
113	Probiotics in Gastrointestinal Disorders. Hospital Practice (1995), 2010, 38, 122-129.	1.0	18
114	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut, 2010, 59, 325-332.	12.1	588
115	Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation â€” a 12â€week, randomized, doubleâ€blind, placeboâ€controlled study. Alimentary Pharmacology and Therapeutics, 2009, 29, 315-328.	3.7	312
116	Irritable bowel syndrome: Role of food in pathogenesis and management. Journal of Digestive Diseases, 2009, 10, 237-246.	1.5	76
117	Prebiotics for irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2009, 3, 487-492.	3.0	8
118	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut, 2009, 58, 367-378.	12.1	486
119	Probiotics and Irritable Bowel Syndrome. Bioscience and Microflora, 2009, 28, 119-124.	0.5	2
120	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2009, 104, S8-S35.	0.4	140
121	What is the evidence for the use of probiotics in functional disorders?. Current Gastroenterology Reports, 2008, 10, 379-384.	2.5	14
122	Gastrointestinal dysfunction in neurological disease: a report of an interdisciplinary international symposium. Neurogastroenterology and Motility, 2008, 6, 55-57.	3.0	1
123	Probiotics in functional gastrointestinal disorders: what are the facts?. Current Opinion in Pharmacology, 2008, 8, 704-708.	3.5	53
124	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ: British Medical Journal, 2008, 337, a2313-a2313.	2.3	454
125	The â€Conâ€™ case. The Rome Process and Functional Gastrointestinal Disorders: the barbarians are at the gate!. Neurogastroenterology and Motility, 2007, 19, 793-797.	3.0	31
126	Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?. Gastroenterology, 2006, 130, 304-311.	1.3	544

#	ARTICLE	IF	CITATIONS
127	Irritable bowel syndrome: The burden and unmet needs in Europe. Digestive and Liver Disease, 2006, 38, 717-723.	0.9	80
128	Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 1581-1590.	0.4	739
129	Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?. Chinese Journal of Digestive Diseases, 2005, 6, 122-132.	1.0	54
130	Review article: quality-of-life issues in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2005, 22, 41-47.	3.7	45
131	Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 436-437.	1.7	6
132	Critical care dysmotility: abnormal foregut motor function in the ICU/ITU patient. Gut, 2005, 54, 1351-1352.	12.1	17
133	Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology, 2005, 128, 541-551.	1.3	1,276
134	Review article: gastric emptying in functional gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 2004, 20, 56-60.	3.7	54
135	Intestinal motility: Normal and disturbed patterns. Chinese Journal of Digestive Diseases, 2003, 4, 1-4.	1.0	1
136	New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. Alimentary Pharmacology and Therapeutics, 2003, 17, 43-51.	3.7	18
137	Factors That Influence Therapeutic Outcomes in Symptomatic Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2003, 98, S24-S30.	0.4	32
138	From comic relief to real understanding; how intestinal gas causes symptoms. Gut, 2003, 52, 1659-1661.	12.1	24
139	Aerophagia and intestinal gas. Current Treatment Options in Gastroenterology, 2002, 5, 259-265.	0.8	6
140	Small intestinal transplantation. Current Gastroenterology Reports, 2001, 3, 408-411.	2.5	3
141	The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2000, 14, 1503-1509.	3.7	83
142	Acute intestinal pseudo-obstruction. Current Treatment Options in Gastroenterology, 2000, 3, 273-285.	0.8	16
143	Is there a future for a national scientific medical journal in Ireland?. Irish Journal of Medical Science, 2000, 169, 12-12.	1.5	0
144	Pharmacotherapy of gastroparesis. Expert Opinion on Pharmacotherapy, 2000, 1, 881-887.	1.8	14

#	ARTICLE	IF	CITATIONS
145	Title is missing!. <i>Antonie Van Leeuwenhoek</i> , 1999, 76, 279-292.	1.7	320
146	Chronic intestinal pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 239-250.	0.8	16
147	Efficacy of Prolonged Administration of Intravenous Erythromycin in an Ambulatory Setting as Treatment of Severe Gastroparesis: One Center's Experience. <i>Journal of Clinical Gastroenterology</i> , 1999, 28, 131-134.	2.2	64
148	Transdermal delivery of erythromycin lactobionate-implications for the therapy of gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 589-592.	3.7	10
149	Constipation in parkinson's disease: Objective assessment and response to psyllium. <i>Movement Disorders</i> , 1997, 12, 946-951.	3.9	190
150	Motility, heartburn and dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 41-50.	3.7	9
151	An evaluation of an ambulatory manometry system in assessment of antroduodenal motor activity. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1531-1537.	2.3	24
152	Symptoms and gastric function in dyspepsia â€” goodbye to gastroparesis?. <i>Neurogastroenterology and Motility</i> , 1996, 8, 273-275.	3.0	15
153	Letters to the editor. <i>Muscle and Nerve</i> , 1996, 19, 109-114.	2.2	0
154	Anorectal function in fluctuating (onâ€”off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography. <i>Movement Disorders</i> , 1995, 10, 650-657.	3.9	72
155	Glucagon, stress, and portal hypertension. <i>Digestive Diseases and Sciences</i> , 1995, 40, 1816-1823.	2.3	9
156	Dysphagia and diffuse oesophageal spasm as the presenting manifestation of the glucagonoma-neuropathy syndrome. <i>Ecological Management and Restoration</i> , 1995, , .	0.4	0
157	Anorectal manometry in the assessment of anorectal function in Parkinson's disease: A comparison with chronic idiopathic constipation. <i>Movement Disorders</i> , 1994, 9, 655-663.	3.9	61
158	Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: Differing effects of cyclosporine and FK 506. <i>Hepatology</i> , 1994, 19, 1381-1389.	7.3	27
159	The clinical pharmacology of motility disorders: The perils (and pearls) of prokinesia. <i>Gastroenterology</i> , 1994, 106, 1112-1114.	1.3	15
160	Defecatory function in Parkinson's disease: Response to apomorphine. <i>Annals of Neurology</i> , 1993, 33, 490-493.	5.3	120
161	Gastrointestinal symptoms in parkinson disease: 18â€”month followâ€”up study. <i>Movement Disorders</i> , 1993, 8, 83-86.	3.9	124
162	Gastric Compliance and Motility in the Portal Hypertensive Rat. <i>Journal of Investigative Surgery</i> , 1992, 5, 109-114.	1.3	7

#	ARTICLE	IF	CITATIONS
163	Antroduodenal manometry. Digestive Diseases and Sciences, 1992, 37, 1305-1308.	2.3	3
164	Antroduodenal manometry. Digestive Diseases and Sciences, 1992, 37, 1927-1927.	2.3	0
165	Antroduodenal manometry. Digestive Diseases and Sciences, 1992, 37, 20-28.	2.3	108
166	Development and Evaluation in an ex vivo Rat Model of a Technique for the Endoscopic Assessment of Mucosal Defense in Man. Scandinavian Journal of Gastroenterology, 1991, 26, 353-360.	1.5	0
167	Gastrointestinal symptoms in Parkinson's disease. Movement Disorders, 1991, 6, 151-156.	3.9	338
168	Assessment of Intestinal Failure Patients. , 0, , 115-121.		0
169	Intestinal Failure: Definitions and Classifications. , 0, , 55-65.		0
170	Intestinal Adaptation. , 0, , 45-54.		6
171	Immunology of the Small Intestine. , 0, , 33-44.		0
172	Basic Physiology of Motility, Absorption and Secretion. , 0, , 20-32.		0
173	The History of Intestinal Failure and Transplantation. , 0, , 1-10.		0
174	Intestinal Failure-Associated Liver Disease. , 0, , 191-200.		4
175	Infections in Small Bowel Transplant Recipients. , 0, , 297-304.		1
176	Intestinal Failure Related to Bariatric Surgery. , 0, , 93-98.		0
177	Motility Disorders. , 0, , 107-113.		0
178	Vascular Access, Including Complications. , 0, , 142-150.		2
179	Enteral Support for Children with Intestinal Failure. , 0, , 151-159.		2
180	The Use of Enteral Nutrition in the Adult with Intestinal Failure. , 0, , 160-166.		1

#	ARTICLE	IF	CITATIONS
181	Management of Complex Fluid and Electrolyte Disturbances. , 0, , 185-190.		1
182	Psychiatric Issues in the Assessment of the Patient with Intestinal Failure. , 0, , 201-205.		2
183	Munchausen Syndrome by Proxy. , 0, , 206-211.		0
184	The Role of Humoral Factors in Intestinal Adaptation. , 0, , 223-228.		0
185	Autologous Reconstruction of the GI Tract. , 0, , 229-241.		0
186	Isolated Small Bowel Transplantation and Combined Liver-Small Bowel Transplantation. , 0, , 254-261.		1
187	Living Donor Intestinal Transplantation. , 0, , 262-269.		0
188	Isolated Liver Transplantation for Intestinal Failure-Associated Liver Disease. , 0, , 270-274.		0
189	Preservation of the Intestine. , 0, , 275-282.		1
190	Immediate Postoperative Care of the Intestinal Transplant Recipient. , 0, , 283-289.		1
191	Surgical Complications of Intestinal Transplantation. , 0, , 290-296.		0
192	Immunosuppression after Intestinal Transplantation. , 0, , 305-313.		0
193	Immunology of Intestinal Allograft Rejection. , 0, , 314-321.		0
194	Histopathology of Intestinal Transplantation. , 0, , 322-330.		0
195	Long-Term Management of Intestinal Transplant Recipients. , 0, , 331-341.		0
196	Management of Posttransplant Lymphoproliferative Disease. , 0, , 342-348.		0
197	Results of Intestinal Transplantation. , 0, , 349-356.		0
198	Psychosocial Assessment and Management of the Transplant Patient/Family in Intestinal Transplantation. , 0, , 357-362.		0

#	ARTICLE	IF	CITATIONS
199	Financial, Economic and Insurance Issues Pertaining to Intestinal Transplantation: When is too much not enough?. , 0, , 363-377.		1
200	Causes of Intestinal Failure in the Newborn. , 0, , 66-76.		0
201	Congenital Enteropathies Causing Permanent Intestinal Failure. , 0, , 77-87.		0
202	Inflammatory Bowel Disease and the Short Bowel Syndrome. , 0, , 99-106.		1
203	Guidelines for Home Parenteral Nutrition Support in Chronic Intestinal Failure Patients. , 0, , 122-129.		1
204	Home Parenteral Nutrition: Complications, Survival, Costs and Quality of Life. , 0, , 130-141.		7
205	Luminal Nutrient Factors in Intestinal Adaptation and their use in Therapy. , 0, , 213-222.		0
206	Causes of Intestinal Failure in the Adult. , 0, , 88-92.		0
207	The Enteric Flora in Intestinal Failure. , 0, , 167-184.		4